<DOC>
	<DOCNO>NCT00206726</DOCNO>
	<brief_summary>This multi-center , Phase II , open label trial evaluate efficacy safety alemtuzumab fludarabine treatment B-cell chronic lymphocytic leukemia ( B-CLL ) patient receive least one prior therapy . Treatments administer 28-day cycle 4-6 cycle , evaluation Cycle 4 permit re-staging . Alemtuzumab fludarabine administer Days 1-5 cycle . Patients assessed response time re-staging Cycle 4 end Cycle 6 . At time re-staging , patient achieve Partial Remission ( PR ) Stable Disease ( SD ) give additional 2 cycle treatment patient demonstrate presumptive sign Complete Remission ( CR ) receive treatment follow response .</brief_summary>
	<brief_title>Alemtuzumab/Fludarabine Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia ( B-CLL )</brief_title>
	<detailed_description>As April , 2011 Bayer transfer record Genzyme . Genzyme sponsor trial . NOTE : This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient must confirm BCLL . Patients must receive least one prior therapy must require treatment active disease Treatment anticancer agent ( chemotherapy , monoclonal antibody , etc ) within 4 week start study . History significant allergic reaction antibody therapy require discontinuation antibody therapy History human immunodeficiency virus ( HIV ) positivity . Active infection require treatment Pregnancy lactation Other severe , concurrent disease mental disorder Central nervous system involvement chronic lymphocytic leukemia ( CLL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>